Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parecoxib vs Indomethacin for Post-ERCP Pancreatitis
NCT06623513Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Oct 2024
- Primary completion
- Sep 2026
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised trial of parecoxib in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Shanghai General Hospital. Primary endpoint: Incidence of Post-ERCP Pancreatitis. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
parecoxib
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT06623513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06623513.